- Facing pharmacy trends for the remainder of the year
- Cardinal Health’s Independence Medical unit helps pharmacy owners tap into growing home healthcare market
- Eat Well, Test Well: Bayer HealthCare and dLife Healthcare Solutions launch diabetes resource
- Former CMS, FDA chief McClellan delivers keynote at Cardinal Health RBC
- Research Now launches diabetes panel
NEW YORK The name of the game in diabetes management is compliance. For patients and their healthcare advocates/practitioners, compliance translates into better health outcomes that will prove to be considerably less costly over the life of the patient. And for retailers and blood-glucose meter manufacturers, compliance translates into a high-frequency/high-marketbasket consumer as compared with the average pharmacy patron.
So an article in The New York Times questioning the validity of meters sold in the United States could be cause for considerable concern — if American diabetics have less faith in the accuracy of their meters, then they’re likely to be less compliant in testing. And diabetics who don’t have their blood-sugar levels in check would mean poorer health, higher healthcare costs, a decline in pharmacy trips and the loss of that highly-coveted diabetes consumer.
As expressed in the Times report, creating a lack of faith in meter results by questioning meter efficacy is what the agency is attempting to avoid.